Business Context and Reporting Period
Company: ORAMED PHARMACEUTICALS INC.
Filing Type: Form 8-K (Current Report)
Date of Report: August 2, 2007
Event: Completion of a private placement of unregistered equity securities.
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance. Key metrics from the transaction include:
- Aggregate Proceeds: US $255,000
- Units Issued: 510,000 Units
- Price per Unit: US $0.50
- Unit Composition: One common share and one share purchase warrant per Unit.
- Warrant Terms: Exercisable into one additional common share at US $0.75 per share until August 2, 2010.
- Finders Fee: 10,000 shares issued to one non-US individual.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of this specific transaction.
Material Changes
The primary material change is the increase in outstanding equity and cash reserves resulting from the private placement closed on August 2, 2007. The transaction was conducted as an offshore transaction relying on Regulation S and/or Section 4(2) of the Securities Act of 1933, involving six non-U.S. persons.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the unregistered nature of the securities sold. The transaction was executed under exemptions from registration.
Investor Verification Checklist
- Verify the total number of outstanding shares post-transaction (510,000 new shares plus 10,000 finder fee shares).
- Confirm the dilution impact of the 510,000 warrants exercisable at $0.75.
- Review the use of proceeds for the $255,000 raised to ensure alignment with operational needs.
- Check subsequent filings for any updates on the exercise of warrants or further capital raises.